Sanofi opens dialogue on R&D cuts in France in September
This article was originally published in Scrip
Brace for September: traditionally known as la rentrée in France as children return to school, for several hundred R&D staff at Sanofi it will probably mean precisely the opposite – an unwelcome order to return home.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.